A Study to Examine the Duration of Effect of PrEP-001 in Healthy Subjects Challenged With HRV-16

Viral Upper Respiratory Tract Infection Clinical Trial

Official title:
A Phase IIa, Randomised, Double-blind, Placebo-controlled Outpatients Study to Investigate the Duration of Effect and Safety of PrEP-001 Given Prophylactically in Healthy Subjects, Subsequently Challenged With Human Rhinovirus (HRV-16)

Status Completed

Clinical Trial Summary

A study to examine the duration of effect of PrEP-001 in healthy subjects challenged with HRV-16

Clinical Trial Description

A phase IIa, randomised, double-blind, placebo-controlled study using outpatient setting to assess the prophylactic effect of repeated intranasal dosing of PrEP-001 in healthy subjects, subsequently challenged with HRV-16, on the changes in clinical symptoms when compared to placebo at two different dosing regimens ;

Study Design

Related Conditions & MeSH terms

Common Cold
Respiratory Tract Infections
Viral Upper Respiratory Tract Infection

Clinical Trial Details

NCT number	NCT03338556
Study type	Interventional
Source	Prep Biopharm Limited
Contact
Status	Completed
Phase	Phase 2
Start date	April 6, 2016
Completion date	September 30, 2016

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05859984` - To Evaluate the Clinical Efficacy and Safety of Recombinant Human Interferon ω Spray in Treatment of Viral Upper Respiratory Tract Infection in Children	Phase 2
Completed	`NCT02756221` - Probiotic Supplementation and Endurance Performance in Cyclists and Masters Runners	N/A
Withdrawn	`NCT03026205` - ARMS-I (a Formulation of Cetylpyridinium Chloride -CPC)	Phase 2
Completed	`NCT00656929` - Randomized Controlled Trial of Vitamin D3 Supplementation for Viral Upper Respiratory Tract Infections (URI) Prevention	N/A